Trusted Resources: Education
Scientific literature and patient education texts
Comparison of Nusinersen and Evrysdi in the Treatment of Spinal Muscular Atrophy
source: E3S Web of Conferences
year: 2021
authors: Xiaoying Zhu
summary/abstract:Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disease that commonly affects children, and usually worsens with age that often leads to permanent disability and death for many of the SMA patients. Recently, two drugs are developed to improving the quality of life of SMA sufferers: Evrysdi and Nusinersen. This study is identified by a systematic literature review to compare two treatments. The comparison attempts to focus on mechanism, administration and clinical trials. The trials include the ENDEAR study for Nusinersen, and the FIREFISH study for Evrysdi. Due to the different baselines of two trials, matching-adjusted indirect comparison (MAIC) is used to “weighted” baseline characteristics to match each other across all the studies. Each of the trials highlighted the effectiveness for comparison. Both Nusinersen and Evrysdi have had a major and positive impact on improving the quality of life of SMA, and both therapies have been shown to be highly effective. Moreover, the indirect comparison with Matching Adjustment Indirect Comparison shows that Risdiplam is more effective as compared to Nusinersen. Nonetheless, the comparison is still inaccurate due to lack of real-world evidence from patients.
organization: Healthcare decision and analysis, USA
DOI: 10.1051/e3sconf/202127103035
read more
Related Content
-
Once-Daily Risdiplam Beneficial in Patients With Types 2 and 3 SMA: LancetOnce-Daily Risdiplam is beneficial in pa...
-
A ‘Miracle’: Spinraza Gives Boy, Now 5, a Chance to Grow UpIt’s now been more than four years sin...
-
Safety and Efficacy Data Published for Novel Nusinersen Drug Delivery Method for Spinal Muscular Atrophy PatientsA recently published paper details the s...
-
Despite Taking Spinraza, SMA Type 1 Children Show Nonmotor ProblemsDespite its well-reported benefits in mo...
-
Nonrespiratory Complications of Nusinersen-Treated Spinal Muscular Atrophy Type 1 PatientsBackground: Emergence of new treatments ...
-
Your Guide to Spinal Muscular Atrophyhttps://simedhealth.com/sites/default/fi...
-
Risdiplam for the Use of Spinal Muscular AtrophySpinal muscular atrophy (SMA) is one of ...